Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe California Medical Innovations Institute, Inc.

About this trial

The objective is to determine the length-tension properties of the anal sphincters using Fecobionics in normal subjects and FI patients during anal distension and during simulated evacuation. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. Fecobionics combines several existing tests to provide novel insight into anorectal function. The purpose for the development was to overcome the technological controversies and disagreement between various tests and unphysiological test conditions. The aim was to imitate defecation as much as possible to the natural process. Fecobionics was developed to simulate stool and to provide the driving pressure and resulting deformations of stool along with a measure of an objective anorectal angle during defecation in a single examination. Fecobionics makes it possible to describe objectively, without disturbing the defecation process, the opening characteristics and pressure signatures during initial entry into the relaxing anal canal.

The overall goal is to provide mechanistic understanding of defecation in health and defecatory disorders. It exceeds previous attempts to make artificial stool for evaluation of defecation (BET and FECOM) and integrates other technologies as well. It was designed to have a consistency and deformability of Type 4 (range type 3-5) on the Bristol stool form scale. The range from types 3-5 is found in 70% of normal subjects. A major novelty is that Fecobionics measures pressures in axial direction; i.e., in the flow direction.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Subject must provide written informed consent;

Willing and able to undergo required study tests, surveys, and procedures;

Age > 18 years of age.

Disqualifiers

Female who is pregnant;

Prior anorectal surgery;

Prior bowel resection;

History of chronic constipation;

Trial design

Design model

Single group

Treatments tested in this trial

  • Fecobionics

    Device

    Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.

Treatment groups

155 Participants
are divided into 2 treatment groups
Group A: Fecobionics studyExperimental treatment 1 intervention
Group B: Feco BFTActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Length-tension properties of the anal sphincter will be reported

Time frame
1.5 year
2

Front-rear pressure difference (in cmH2O) will be measured

Fecobionics contain pressure sensors in front end and rear end which can measure pressures

Time frame
1.5 year

Secondary outcomes

1

Anorectal angle (in degree) will be measured

Fecobionics contain motion processing units with gyroscopes and accelerometers, which can measure angles

Time frame
1.5 year
2

Expulsion velocity (in mm/s) will be reported

Time frame
1.5 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The California Medical Innovations Institute, Inc.

Lead sponsor

Augusta University Medical Center

Collaborator